Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00272792 · ClinicalTrials.gov registry record · Phase 3
Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet
A Phase 3 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
NCT00272792 is a Phase 3 study that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 45 participants.
The verdict
NCT00272792, a Phase 3 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the ability of Phenoptin to increase phenylalanine (phe) tolerance in children with phenylketonuria who are following a phe-restricted diet.
Interventions
- DRUG Placebo
- DRUG Sapropterin Dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00272792
The ClinicalTrials.gov registry entry for NCT00272792 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00272792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00272792 about?
NCT00272792 is a clinical study titled "Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet". The primary objective of this trial is to evaluate the ability of Phenoptin to increase phenylalanine (phe) tolerance in children with phenylketonuria who are following a phe-restricted diet.
What is the current status of trial NCT00272792?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2006-02. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00272792?
The interventions under investigation include: Placebo (DRUG), Sapropterin Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT00272792?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.